(111)In-ABY-002

N/A

Report date: 2025/11/20 16:02:39

NME

Base Information

Drug Name(111)In-ABY-002

Drug Alias Name(111)In-ABY-002

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSingle-photon emission-computed tomography enhancersReceptor protein-tyrosine kinase erbB-2 antagonistsPositron-emission tomography enhancers

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesAffibody Ab

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffibody Ab

Active IndicationsN/A

Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A